Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New dialysis filter aims to cut inflammation and protect hearts in kidney patients

NCT ID NCT07679763

Disease control Sponsor: Gazi University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 01, 2026 · Last updated Sep 10, 2026 · Updated 3 times

Summary

This study tests whether a newer type of dialysis filter (medium cut-off membrane) can reduce inflammation and improve heart function better than the standard filter in people with end-stage kidney disease. Thirty adults on maintenance hemodialysis will use each filter for three months in a crossover design. Researchers will measure blood markers of inflammation and blood vessel health, along with artery stiffness, muscle strength, and quality of life.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Medium cut-off (MCO) hemodialysis membrane (ELISIO™ MCO series)
What this could lead to
If MCO membranes prove better, this could lead to improved inflammation control and heart health for people on long-term dialysis.
What could go wrong
This is a small, early-stage crossover study with only 30 participants, so results may not apply broadly. The intervention is a device, not a drug, so benefits may be modest.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2026

Expected to finish

Jan 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18 to 80 years. * Receiving maintenance hemodialysis for at least 6 months. * Clinically stable and receiving thrice-weekly hemodialysis. * Able to comply with study procedures, questionnaires, and scheduled assessments. * Able and willing to provide written informed consent. Exclusion Criteria: * Acute infection at screening or enrollment. * Major surgery within the previous 3 months. * Active malignancy requiring ongoing treatment. * Terminal illness with limited life expectancy. * Physical or cognitive impairment preventing completion of study procedures or questionnaires. * Inability or unwillingness to provide written informed consent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cardiovascular diseases (CVD) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cardiovascular disorder chronic kidney disease end stage renal failure Inflammation inflammatory disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cardiovascular diseases (CVD) End-stage kidney disease (ESKD) Hemodialysis Inflammation

Contacts and locations

Locations

  • Gazi University Faculty of Medicine, Department of Nephrology, Hemodialysis Unit

    Ankara, Ankara, 06500, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.